Since the first discovery that human pluripotent stem cells (hPS cells) can differentiate to cardiomyocytes, efforts have been made to optimize the conditions under which this process occurs. One of the most effective methodologies to optimize this process is reductionist simplification of the medium formula, which eliminates complex animal-derived components to help reveal the precise underlying mechanisms. Here we describe our latest, cost-effective and efficient methodology for the culture of hPS cells in the pluripotent state using a modified variant of chemically defined E8 medium. We provide exact guidelines for cell handling under these conditions, including non-enzymatic EDTA passaging, which have been optimized for subsequent cardiomyocyte differentiation. We describe in depth the latest version of our monolayer chemically defined small molecule differentiation protocol, including metabolic selection-based cardiomyocyte purification and the addition of triiodothyronine to enhance cardiomyocyte maturation. Finally, we describe a method for the dissociation of hPS cell-derived cardiomyocytes, cryopreservation, and thawing. C 2015 by John Wiley & Sons, Inc.
INTRODUCTION
This unit describes methods for the culture and cardiac differentiation of human pluripotent stem cells (hPS cells), which include human embryonic stem cells (hES cells) and human induced pluripotent stem cells (hiPS cells) (Burridge et al., 2014) . In the Basic Protocol of this unit, hiPS cells are grown in a modified version of chemically defined E8 medium on low-density (1:400) Matrigel. E8 medium is changed every day, and the cells are grown for 3 to 4 days, by which time they become 65% to 85% confluent; afterwards, cells are either passaged or differentiated. Cells are passaged non-enzymatically using EDTA, and a Rho-associated protein kinase inhibitor (10 μM Y27632) is used for 24 hr after splitting to improve cell survival and split ratio reliability and to reduce selective pressure. Cells are passaged at a 1:15 split ratio (equal to seeding densities of ß1.25 × 10 4 cells per cm 2 ). The timing for splitting and subsequent 3 to 4 days of growth are crucial to the efficiency of the protocol.
In this protocol, human iPS cells are differentiated as a monolayer, which eliminates embryoid body formation variability (Burridge et al., 2007) but requires careful control of pluripotent cell seeding density. Differentiation towards cardiomyocyte lineage is induced using small molecules to modulate the WNT signaling pathway, first with a GSK3B inhibitor to potentiate WNT signaling and then 2 days later with a WNT inhibitor to attenuate WNT signaling (Gonzalez et al., 2011; Lian et al., 2012; Burridge et al., 2014) . The basic culture medium used throughout cardiac differentiation and cardiomyocyte maintenance is CDM3 (Burridge et al., 2014) , a chemically defined medium consisting of RPMI 1640, rice-derived recombinant human albumin, and Lascorbic acid 2-phosphate. This protocol is designed to be very simple and cost effective. It is highly reproducible, and has been shown to generate ß80% to 95% TNNT2 + cells in >200 hiPS cell lines that we have tested. We have empirically demonstrated that higher splitting ratios (lower seeding densities) result in higher TNNT2 + cell yields. At day 0, the medium is changed to CDM3-C containing 6 μM CHIR99021 (GSK3B inhibitor). After 48 hr (day 2), the medium is changed to CDM3-C59 containing 2 μM Wnt-C59 (WNT inhibitor). The medium is then replaced with CDM3 every other day, and contracting cells will be seen from day 8 to day 9. From day 10 to day 16, CDM3 is replaced with CDM3-L (with no D-glucose but with L-lactic acid) to metabolically select and purify cardiomyocytes (Tohyama et al., 2013) . From day 20 to day 30, CDM3 is replaced with CDM3-T (with triiodothyronine) to enhance cardiomyocyte maturation (Yang et al., 2014) . Beating cardiomyocytes can be maintained indefinitely in CDM3 (>6 months). The time course of pluripotent growth and cardiac differentiation is shown in Figure 21 .3.1.
The major optimizable factors are the seeding density (1:12 to 1:20), the number of days of pluripotent growth (3 or 4 days), and the narrow range at which the CHIR99021 is effective in this system (5 to 7 μM). A simple experiment is to seed the cells at densities of 1:12, 1:15, and 1:20, treat them with 5 μM, 6 μM, or 7 μM of CHIR99021 during the day 0 to day 2 window, and assess for cell survival and epithelial to mesenchymal transition. We found only a minimal influence of modification of the later steps on differentiation.
Materials
Human induced pluripotent stem cells (hiPS cells; see information in step 1) E8-Y medium (see recipe) E8 medium (without Y27632; see recipe) 0.5 mM EDTA (see recipe) CDM3-C (with CHIR99021; see recipe) CDM3-C59 (with Wnt-C59; see recipe) CDM3-L (without D-glucose, with L-lactic acid; see recipe) Dulbecco's phosphate-buffered saline without Ca or Mg (CMF-DPBS) TrypLE Express (Life Technologies, cat. no. 12605-036) Liberase TH, 260 U/50 mg (Roche, cat. no. 05401151001), resuspend in 10 ml WFI water (Corning, and make 500-μl aliquots; store at −20°C DNase I, 277 U/μl (Life Technologies, cat. no 18047-019) CDM3 (see recipe) Fetal bovine serum (FBS; Life Technologies, cat. no. 10082-147) (B) Representative images of hiPS cells seeded at a 1:15 split ratio in E8, followed by differentiation using the CDM3 protocol.
8. With a P-1000 (1-ml) pipet tip, add 1 ml of E8-Y medium to the well, and blast medium against cell surface to dissociate cells (cells should come off easily after pipetting in this way ß5 times). For a 1:15 split, remove 200 μl and discard; for a 1:20 split, remove 400 μl and discard. Top up well to 12 ml with E8-Y.
9. Plate out cells at 1 ml per well into two new Matrigel-coated 6-well plates and top up each well to 2 ml with E8-Y. 21. Pipet up and down with a P-1000 (1-ml) pipet tip ß10 times to dislodge cells and to break up aggregates. Avoid forming bubbles.
22. Return cells to incubator for another 5 min at 37°C.
23. Pipet up and down with a P-1000 (1-ml) pipet tip ß10 times to dislodge cells and to break up aggregates. Avoid forming bubbles.
24. Transfer cells to a 15-ml conical tube, top up with CDM3, and centrifuge 5 min at 300 × g, room temperature.
25. Resuspend in 1 ml CDM3 and pipet up and down with a P-1000 pipet tip ß10 times to release single cells.
In our experience, the addition of Y27632 did not improve cardiomyocyte cell survival after dissociation.
26. Pass cells through a 100-μm cell strainer. Thawing cardiomyocytes 32. Remove vial from liquid nitrogen and place in a 37°C water bath for approximately 1 min until there is just a sliver of ice left.
33. Transfer vial contents to a 15-ml conical tube and add ß10 ml of CDM3 medium supplemented with 20% FBS dropwise.
34. Invert to mix, then centrifuge 4 min at 200 × g, room temperature.
35. Resuspend pellet in CDM3 at a ratio of ß1 ml per million cells to be plated in a Matrigel-coated 12-well plate or equivalent.
36. After 48 hr, replace medium with CDM3 and then change medium every other day.
Expect ß60% survival after thawing.
Days 16 and 18: Change CDM3 medium
37. Aspirate medium in wells.
38. Add 2 ml of CDM3. 20, 22, 24, 26, 39. Aspirate medium in wells.
Days
40. Add 2 ml of CDM3-T.
We have not validated the concentrations and timing of T 3 treatment. It is possible further optimization may improve maturation.

SUPPORT PROTOCOL 1
CHARACTERIZATION OF CARDIOMYOCYTES BY FLOW CYTOMETRY
Cardiomyocytes can be analyzed using flow cytometry (see Fig. 21 .3.2). Day 20 cardiomyocytes are first stained with troponin T (TNNT2) antibodies and labeled with AlexaFluor 488-conjugated goat anti-mouse IgG 1. Follow the manufacturer's instructions for operation of the flow cytometer.
For this procedure, we use a Thermo 5/7 ml bucket with decanting aid, allowing the simultaneous processing of a large number of tubes. 3. Add 1 ml of cold 90% methanol, incubate for 15 min at 4°C, centrifuge as described in step 1, and decant supernatant.
4. Wash with 2 ml 0.5% BSA in CMF-DPBS, centrifuge as described in step 1, and decant supernatant.
5. Repeat step 4.
6. Resuspend the fixed cells in 100 μl of 0.5% BSA/0.1% Triton X-100 in CMF-DPBS containing a 1:200 dilution of TNNT2 mouse monoclonal (13-11) primary antibody, vortex, incubate for 1 hr at room temperature, centrifuge as described in step 1, and decant supernatant.
7. Wash with 2 ml 0.5% BSA/0.1% Triton X-100 in CMF-DPBS, centrifuge as described in step 1, and decant supernatant.
8. Resuspend in 100 μl of 0.5% BSA/0.1% Triton X-100 in CMF-DPBS containing a 1:1000 dilution of AlexaFluor 488 goat anti-mouse IgG 1 , vortex, incubate for 30 min at room temperature, centrifuge as described in step 1, and decant supernatant.
9. Wash with 2 ml 0.5% BSA/0.1% Triton X-100 in CMF-DPBS, centrifuge as described in step 1, and decant supernatant.
10. Repeat step 9.
11. Resuspend cells in 300 μl of 0.5% BSA in CMF-DPBS.
12. Analyze with flow cytometer such as Beckman Coulter CytoFLEX, following instrument manufacturer's instructions.
Expected results are approximately 85% TNNT2 positive cells.
SUPPORT PROTOCOL 2
CHARACTERIZATION BY IMMUNOFLUORESCENT STAINING
Day 15 cardiomyocytes can be evaluated by immunofluorescent staining using antibodies against troponin T (TNNT2) and α-actinin (ACTN2), as shown in Figure 21 .3.2.
Material
Cardiomyocytes (Basic Protocol) Dulbecco's phosphate-buffered saline without Ca or Mg (CMF-DPBS) 4% (w/v) PFA in CMF-DPBS (prepare from 20% PFA; Electron Microscope Sciences, cat. no. 15713-S) 0.5% (v/v) Triton X-100 (Sigma-Aldrich, cat. no. X100) in CMF-DPBS 3% (w/v) BSA (Sigma-Aldrich, cat. no. A3311) in CMF-DPBS TNNT2 (Troponin T) 3. Permeabilize with 0.5% Triton X-100 in CMF-DPBS. Incubate for 15 min at room temperature.
4. Block with 3% BSA in CMF-DPBS, and incubate for 30 to 60 min at room temperature.
5. Stain cells with TNNT2 and ACTN2 antibodies at 1:200 and 1:500 dilution, respectively, in 3% BSA in CMF-DPBS. Incubate for 1 to 3 hr at room temperature or overnight at 4°C.
6. Wash three times with CMF-DPBS, each time for 2 to 3 min.
7. Stain with secondary antibodies at 1:1000 dilution in 3% BSA in CMF-DPBS for 30 to 60 min at room temperature in dark.
8. Wash three times with CMF-DPBS, each time for 2 to 3 min.
9. Adhere coverslip with 1 to 2 drops of Prolong Diamond (with DAPI) and evaluate by fluorescence microscopy. 
REAGENTS AND SOLUTIONS
CDM3-C
To 1 liter RPMI 1640 (Corning 10-040-CM), add: 10 ml CDM3 supplement (see recipe) 600 μl of 10 mM CHIR99021-HCl (Biorbyt, cat. no. orb154612; 6 μM final) in DMSO There is no need to filter sterilize CDM3-C is stable at 4°C for >4 weeks
CDM3-C59
To 1 liter RPMI 1640 (Corning, cat. no. 10-040-CM), add: 10 ml CDM3 supplement (see recipe) 200 μl of 10 mM Wnt-C59 (Biorbyt, cat. no. orb181132; 2 μM final) in DMSO There is no need to filter sterilize CDM3-C59 medium is stable at 4°C for >4 weeks
CDM3-L
To 1 liter RPMI 1640 (no glucose; Invitrogen, cat. no. 11879-020), add: 10 ml CDM3 supplement (see recipe) 4 mM L-lactic acid (Wako Chemicals, cat. no. 129-02666) There is no need to filter sterilize CDM3-L is stable at 4°C for >4 weeks To prepare this medium, make a 1 M stock solution from 10 M L-lactic acid (Wako Chemials, cat. no. 129-02666) by adding 1 M HEPES (Life Technologies, cat. no. 15630-080). Filter sterilize. Add 4 ml of 1 M L-lactic acid to 1 liter CDM3 (see recipe). 1 M L-lactic acid can be stored for >4 weeks in 4°C.
CDM3
To 1 liter RPMI 1640 (Corning, cat. no. 10-040-CM), add 10 ml CDM3 supplement (see recipe). There is no need to filter sterilize. CDM3 medium is stable at 4°C for >4 weeks. Filter sterilize. Make 10-ml aliquots in 15-ml conical tubes and store up to 6 months at −20°C.
CDM3 supplement
CDM3-T
To 1 liter RPMI 1640 medium (Corning, cat. no. 10-040-CM), add: 10 ml CDM3 supplement (see recipe) 1 ml of 2 μg/ml triiodo-L-thyronine (Sigma, cat. no. T6397-100MG) There is no need to filter sterilize CDM3-L is stable at 4°C for >4 weeks 
E8 medium
To 1 liter DMEM/F12 with L-glutamine and HEPES (Corning, cat. no. 10-092-CM), add one thawed 1.5-ml aliquot of E8 supplement prepared as described below for the following final concentrations of additives: 64 μg/ml L-ascorbic acid 2-phosphate (Wako Chemicals, cat. no. 321-44823) 20 μg/ml insulin (Life Technologies, cat. no. A11382ij) 5 μg/ml transferrin (Sigma-Aldrich, cat. no. T3705-1G) 14 ng/ml sodium selenite (Sigma-Aldrich, cat. no. S5261-10G) 100 ng/ml recombinant human FGF2 (Peprotech, cat. no. 100-18B) 2 ng/ml recombinant human TGFβ1 (Peprotech, cat. no. 100-21) 100 ng/ml heparin sodium salt (Sigma H3149-250KU; add from 10 mg/ml stock solution in WFI water) There is no need to filter sterilize The medium is stable at 4°C for >4 weeks Shown below are directions for making 100 1.5-ml E8 supplement aliquots. This will generate 100 liters of E8 medium. (Corning, , 1 ml of 10 mg/ml heparin sodium salt (Sigma, , and 1 ml of 1.4 mg/ml sodium selenite . Make up to 50 ml and add to the ascorbic acid solution. (Peprotech, . TGFβ1 (Peprotech, 
Add 50 ml of room temperature WFI water
Note that insulin will go back through its isoelectric point and come back out of solution as it progresses from pH 3 through to pH 7.4. As it passes pH 7, it will go back in to solution.
If the mixture does not stay in solution, then increase the pH with additional 10 N NaOH (Fisher Scientific, cat. no. SS255-1) (ß200 μl).
Add 48 ml of WFI water (Corning, cat. no. 25-055-CV) to a 50-ml conical tube, and use this to resuspend the contents of ten 1-mg vials of FGF2
Add 2 ml of WFI water to two 100 μg vials of
E8-Y
To 1000 ml E8 medium (see recipe), add 1 ml of 10 mM Y27632 (Biorbyt, cat. no. orb154626) for a final concentration of 10 μM. There is no need to filter sterilize. E8-Y is stable at 4°C for >4 weeks.
EDTA, 0.5 mM
To 500 ml of CMF-DPBS (Corning, cat. no. 21-031-CV) add 500 μl of 0.5 M EDTA (Corning 46-034-CI) for a final concentration of 0.5 mM. Store up to 6 months at room temperature.
Matrigel-coated plates 1. Thaw a bottle of growth factor-reduced Matrigel (Corning, cat. no. 356230) overnight at 4°C, then store it at 4°C. There is no need to aliquot or leave on ice. The bottle of Matrigel will be stable at 4°C for > 3 months. 2. Add 1.25 ml of Matrigel to 500 ml of 4°C DMEM/F12 (enough for 42 plates;
Corning, cat. no. 10-092-CM). Return the Matrigel bottle to 4°C quickly to prevent gelling. 3. Mix the bottle by inversion and plate at 2 ml per well of a 6-well plate (or equivalent amounts for other size plates). 4. Place plates at 37°C for at least 30 min. Plates may be kept here at 37°C for >2 weeks without risk of wells drying out and being unusable.
We use 2 ml per well for 6-well plates so that the plates do not dry out during extended storage at 37°C.
We use Matrigel at a 1:400 dilution. Matrigel is supplied at a 10 to 12 mg/ml stock concentration (see product insert). At a 1:400 dilution and using 2 ml per well, this equates to ß5 μg/cm 2 , which is well within the suitable range (>3 μg/cm 2 ) as previously described (Burridge et al., 2011; Miyazaki et al., 2012) .
COMMENTARY Background Information
Numerous techniques now exist for the cardiac differentiation of hiPS cells, yet only minimal differences in the cardiomyocytes produced have been demonstrated (Burridge et al., 2014) . The chemically defined methodology described here was specifically designed to provide improved control and understanding of the constituents required for cardiomyocyte differentiation while simultaneously providing an 'inert' platform for subsequent drug testing assays and manipulation of factors controlling maturation and subtype specification.
It has yet to be demonstrated what effect differentiation in CDM3 has on the cardiomyocytes it produces in comparison to RPMI+B27 and various other media such as StemPro-34 (Life Technologies) or APEL (StemCell Technologies), each of which has a different basal medium. It is likely that differences in metabolism exist due to the single energy source (glucose) in CDM3 and the lack of pyruvate, galactose, and fatty acids (such as linoleic, linolenic, or oleic acid), resulting in cardiomyocytes relying on glycolysis rather than pyruvate decarboxylation, fatty acid oxidation, the TCA cycle, and/or oxidative phosphorylation. The lack of lipids in the medium may impact cell membrane structures, which may affect successful patch clamp experiments. In addition, the lack of retinoic acid, which is a component of B27, may influence subtype specification, although we have not noted this to date (Burridge et al., 2014) . It has been demonstrated that the addition of creatine, carnitine, taurine, and insulin may be useful for long-term cardiomyocyte culture (Xu et al., 2006) , and this combination is commonly used for rat neonatal ventricular myocytes (RNVMs). We have previously shown that hiPS-cell-derived cardiomyocytes can adhere to a variety of surfaces such as Matrigel, fibronectin, laminin, and collagen, and what role these surfaces have on maturation and subtype specification is still to be established. CDM3 provides a suitable platform for the analysis of each of these variables and high level of control over the cell environment during differentiation. Finally, the costeffectiveness of this protocol makes it highly suitable for large-scale differentiation techniques, both adherent-and suspension-based.
Critical Parameters
The chemically defined pluripotent culture medium E8 (Chen et al., 2011 ) is used to provide a more reproducible environment for pluripotent growth. In our experience, suitable pluripotent growth is the most important variable in achieving efficient subsequent cardiac differentiation. We have made small modifications to the E8 formula. These include (1) replacing human transferrin with a recombinant version and reducing the concentration; (2) selecting a DMEM/F12 with higher levels of sodium bicarbonate so that it does not have to be supplemented (this DMEM/F12 is also supplied in 1-liter bottles, thus eliminating the need for transferring to a larger bottle and filtration); (3) and adding heparin sulfate, which has been demonstrated to stabilize FGF2 at 37°C, preventing the transient decrease in FGF2 levels over 24 hr as previously noted . Our experience indicates that cells grow exceptionally well in this medium, and by negotiating with vendors, we have reduced the cost of E8 by 75% compared to commercial media such as Essential 8 (Life Technologies) or TeSR-E8 (StemCell Technologies).
Passaging hPS cells as single cells and growing them as monolayers is well established (Denning et al., 2006) . The use of EDTA simplifies this process by eliminating the need for centrifugation and dissociating cells to small clumps to improve cell survival (Yu et al., 2011; Beers et al., 2012) . We add 10 μM Y27632 for the first 24 hr after passaging to improve consistency of plating and minimize selective pressure. A number of Rho kinase inhibitors have been shown to improve survival of dissociated hiPS cells, although Y27632 has been demonstrated to be more effective than others such as thiazovivin (Chen et al., 2014) . We use either atmospheric (ß20%) O 2 or physiological (5%) O 2 for pluripotent culture and have not detected a significant impact on subsequent differentiation efficiency. Physiologic 5% O 2 has been demonstrated to improve reprogramming efficiency (Yoshida et al., 2009) , enhance expression of pluripotency genes (Forristal et al., 2010; Narva et al., 2013) , and reduce spontaneous differentiation (Ezashi et al., 2005) , and is optimal when used with mTeSR1 (Stem Cell Technologies) (Ludwig et al., 2006) and E8 (Chen et al., 2011) . Low O 2 also pushes hPS cells to anaerobic glycolysis, resulting in the production of less reactive oxygen species (ROS) and DNA damage, as well as improved genetic stability, and is therefore recommended where available. In particular, even when used for just the first 2 days of the differentiation time course, 5% O 2 can result in inhibition of cardiac differentiation. In our original publication, we demonstrated that a variety of matrices were suitable for cardiac differentiation, although adhesion of cardiomyocytes after day 12 became problematic with all except Matrigel and laminin 511 or 521 (Burridge et al., 2014) . We commonly use Matrigel at a 1:400 dilution, and have not found a more cost-effective alternative. We have found no added benefit in using hES cell-qualified Matrigel.
For cardiac differentiation, we have now used the protocol described here for >200 hiPS cell lines. The protocol is not 100% reproducible, and we have found that some lines go through periods of very successful differentiation followed by periods when they become refractory as they progress from passage 25 to beyond passage 90. Nevertheless, we have not found an hiPS cell line that is completely recalcitrant to differentiation. In 6-well plates, we have also commonly observed that some wells differentiate acceptably, and that others do not differentiate at all or are subject to total cell death. Taken together, these observations suggest that a controlling factor in differentiation efficiency is a combination of passage number, cell density, proliferation rate, and the microenvironment established in response to CHIR99021 and Wnt-C59 treatment.
During the continued development of our protocols, we have used numerous suppliers of recombinant human albumin, and currently use one from ScienCell based on cost. We did not notice any significant differences in differentiation efficiency among the various alterative manufacturers. Similarly, we selected an L-ascorbic acid 2-phosphate that can be purchased in large volumes. Despite continued assessment of CHIR99021 and Wnt-C59 dosing alternatives and timing in a large number of lines, we have not discovered a clearly superior regimen. The differentiation protocol described above was simply the one that most commonly worked with the largest number of the lines.
Metabolic purification is the process of replacing glucose in the medium with lactate, based on the premise that only cardiomyocytes in the culture are able to use the TCA cycle to produce ATP (Tohyama et al., 2013) . As first demonstrated, this method used α-MEM and FBS and showed that cardiomyocytes could survive long term without glucose. The method has not proven to be as straightforward in CDM3 and we have found high levels of variability in survival among lines and differentiations during the metabolic selection. To counteract this, we have reduced the length of time the cells are treated to 4 to 6 days so that we could observe cells to identify early signs of cardiomyocyte death. Additionally, we noted that some differentiation runs contain contaminating non-cardiomyocyte cell types that cannot be removed by metabolic selection. In our original publication (Burridge et al., 2014) , we used sodium DL-lactate to overcome the lack of membrane permeability of L-lactic acid as previously described (Tohyama et al., 2013 ), but we have found that cardiomyocytes cannot be maintained long term using either approach.
Passaging of cardiomyocytes is relatively simple at ࣘ day 15, but we have found that the cells lay down a layer of collagen over time in culture that must be broken down before cells can be isolated, and therefore we recommend the use of Liberase TH and DNase I. By analyzing cryopreservation techniques, we found that cells that are more effectively broken up to single cells have better survival upon thawing, that 10% DMSO+90% FBS is an effective cryopreservation solution, and that the addition of higher percentages of FBS (up to 40%) to the CDM3 for 48 hrs post-thaw improved plating efficiency. Other cryopreservation media such as CryoStor10 have proven effective for the cryopreservation of hiPS cellderived cardiomyocytes, but they are not costefficient. We found that the addition of Y27632 for 24 hr after thawing had a negative effect on cell survival, and this compound is therefore not included.
Troubleshooting
Interline variability and passage number variability in differentiation efficiency: Pluripotent cells must be undifferentiated and growing at a fast rate, ideally achieving 75% to 85% confluence in 3 to 4 days. We have found that lines over passage 25 have a higher differentiation success rate.
Cell death after CHIR99021 treatment: This is commonly due to too high a starting density. For some early-passage lines (<p25), a lower level of CHIR99021 (e.g., 5 μM) may be more suitable.
No signs of epithelial to mesenchymal transition at day 2 were found: Clear signs of EMT are indicative of efficient mesodermal differentiation, and the lack of EMT is likely due to overconfluence of starting cells.
Cell death during late differentiation (days 6 to 8): This can be observed in lowpassage (<p25) lines, and therefore we recommend repeating differentiation.
No beating cells: If cells are not contracting by day 10, discard the plate and repeat differentiation. If this occurs repeatedly, try higher (1:20) or lower split ratio (1:12) or varying the level of CHIR99021 (5 to 7 μM).
Total cell death during metabolic selection: There is variability in how long cells can survive the metabolic (L-lactic acid) selection, and we recommend reducing the number of days in CDM3-L medium.
Anticipated Results
Differentiation should produce 1 to 2 million cardiomyocytes per well for a 6-well plate. Cardiomyocyte purity after metabolic selection will be >90% based on TNNT2 flow cytometry. Cardiomyocytes will stain positive for cardiac markers such as TNNT2 and ACTN2. Cells will beat at ß50 beats per minute-slower at lower temperatures, and faster at higher temperatures. Cardiomyocytes will demonstrate chronotropic responses to drugs such as norepinephrine. Toxicity to known cardiotoxic drugs will increase as the cells age (e.g., from day 30 to day 90). After cryopreservation, cell survival will be ß60%, and cells will regain contraction in 2 to 5 days.
Time Considerations
This full protocol takes 19 days from passage of hiPS cells through to dissociation/cryopreservation of cardiomyocytes.
iPS Cell Models
21.3.13
After thawing cells, it can take 2 weeks for proliferation to reach a suitable rate for successful differentiation. Medium should be changed daily for pluripotent cells; this protocol is not compatible with skipping days or 'weekendfree' schedules. Contracting cells will be noted at approximately day 9 of differentiation.
